Create account

Coverage dated October 5, 2026 to October 6, 2026

STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Headline from STAT

Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.

STAT's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

4 articles, oldest first.

  1. STAT

    STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market (opens STAT)

    Published

    STAT's feed description

    Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.

  2. STAT

    STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more (opens STAT)

    Published

    STAT's feed description

    Vaxcyte said its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merck

  3. Investor's Business Daily

    Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck.

  4. Quartz

    Vaxcyte stock surged after its pneumococcal vaccine passed a key phase 3 test (opens Quartz)

    Published

    Quartz's feed description

    VAX-31 matched or beat Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all measured strains in the OPUS-1 trial

STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market | Since Then